Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Kevin Lynch
University of Virginia, Department: Pharmacology
Should you be removed from our database? Contact us at [email protected]. Read more below.
SphynKx Therapeutics, LLC
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Lynch is the cofounder of SphynKx Therapeutics. This NIH grant focus is the biology of sphingosine 1-phosphate (S!P) and improvement of SphK (sphingosine kinase) inhibitors. This is the commercial focus of SphynKx, the commercialization of SphK inhibitors. Thus the results obtained on this project could substantially impact the financial interest of SphynKx. The SFI in SphynKx could impact the design, conduct or reporting and compromise objectivity.
Controlling sphingosine 1-phosphate synthesis and trafficking
Project Narrative Sphingosine 1-phosphate (S1P) is a signaling molecule that circulates in blood and is implicated in multiple human diseases including cancer, kidney disease, viral infections, and sepsis. Interfering with S1P signaling in white blood cells (lymphocytes) is the basis of a medicine for multiple sclerosis. We hypothesize that ?drugging? S1P signaling at additional nodes, e.g. blockade of S1P synthesis (achieved by inhibiting the sphingosine kinases (SphK1, SphK2)) or inhibition of transport via SPNS2, is a route to additional therapeutic agents. Our preliminary data with our ?lead? SphK inhibitors indicates that SphK2 inhibition might prevent kidney disease progression; we expect that SphK1 or SPNS2 inhibitors may lead to treatment of additional diseases such as sickle cell or autoimmune diseases. Therefore, the goal of this project is to make drug-like compounds to enable validation of the S1P pathway as a drug target so that commercial entities will be motivated to pursue programs to advance new S1P signaling-targeted agents into clinical trials.
Filed on September 01, 2016.
Tell us what you know about Kevin Lynch's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.